{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-355635","form_type":"8-K","ticker":"IRIX","cik":"0001006045","company_name":"IRIDEX CORP","filed_at":"2026-08-18T20:51:26+00:00","discovered_at":"2026-08-18T20:52:03.294185+00:00","generated_at":"2026-08-18T20:52:09.953348+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Iridex Q2 revenue down 7% to $12.6M; glaucoma G6 up 19%, retina weak","bullets":["Total revenue $12.6M, down 7% YoY; net loss $1.3M ($0.07/share) vs $1.0M loss prior year.","Cyclo G6 family revenue $3.9M (+19% YoY) on 17,700 probes sold (+35% volume); retina revenue $6.5M vs $8.0M.","Non-GAAP adjusted EBITDA loss $0.4M vs +$21K prior year; operating cash flow positive in Q2.","Reaffirms FY2026 revenue guidance $51-53M; adjusted opex $19-19.5M; cash $4.7M.","Retina decline due to Middle East disruptions and China sell-through; expects improvement with Pascal platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-355635","json":"https://secwatch.observer/filing/0001193125-26-355635.json","markdown":"https://secwatch.observer/filing/0001193125-26-355635.md","text":"https://secwatch.observer/filing/0001193125-26-355635.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006045/000119312526355635/0001193125-26-355635-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006045/000119312526355635/irix-20260818.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-18T20:52:09.953348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}